Get the Stockscreener App
0.00
100.00%
-11.00
Evoke Pharma Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
See More
Previous Close:
$11.00
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$18.95M
Revenue:
$8.62M
Net Income/Loss:
$-6.15M
P/E Ratio:
0.00
EPS:
-11.03
Net Cash Flow:
$-5.32M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$11.00
Evoke Pharma Inc Stock (EVOK) Company Profile
Name
Evoke Pharma Inc
Sector
Phone
858-345-1494
Address
420 STEVENS AVENUE, SOLANA BEACH, CA
Compare EVOK vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVOK
Evoke Pharma Inc
|
0.00 | 18.95M | 8.62M | -6.15M | -5.32M | -11.03 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.89 | 56.23B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
127.42 | 55.85B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
10.98 | 48.36B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.69 | 40.01B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
485.36 | 20.62B | 3.13B | 1.27B | 1.12B | 26.39 |
Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-22-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-05-19 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-08-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Oct-19-17 | Resumed | FBR & Co. | Buy |
| Mar-16-17 | Reiterated | Rodman & Renshaw | Buy |
| Jan-30-17 | Upgrade | Laidlaw | Neutral → Buy |
| Jan-05-17 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Dec-23-16 | Reiterated | Rodman & Renshaw | Neutral |
| Jul-19-16 | Reiterated | FBR Capital | Outperform |
| Jul-19-16 | Downgrade | Noble Financial | Buy → Hold |
| Jul-18-16 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Mar-16-16 | Initiated | Northland Capital | Outperform |
| Mar-14-16 | Reiterated | Ascendiant Capital Markets | Buy |
| Feb-17-16 | Resumed | FBR Capital | Outperform |
| Dec-03-14 | Reiterated | MLV & Co | Buy |
| Nov-07-14 | Initiated | MLV & Co | Buy |
| Apr-22-14 | Initiated | Laidlaw | Buy |
| Nov-19-13 | Initiated | Aegis Capital | Buy |
View All
Evoke Pharma Inc Stock (EVOK) Latest News
Market Recap: Is Artivion Inc stock undervalued right now2025 Technical Patterns & Technical Pattern Alert System - baoquankhu1.vn
Gastroparesis Treatment Market 2026-2033: Growth Overview, - openPR.com
Income Plays: What is Evoke Pharma Incs 5 year growth outlook2025 Volatility Report & Verified Short-Term Plans - baoquankhu1.vn
Can Evoke Pharma Inc. continue delivering strong returnsCPI Data & High Conviction Investment Ideas - mfd.ru
How cyclical is Evoke Pharma Inc.’s revenue streamQuarterly Performance Summary & Consistent Return Strategy Ideas - mfd.ru
Institution Moves: Can Evoke Pharma Inc grow without dilutionWeekly Investment Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Moving Averages: Is Evoke Pharma Inc a speculative investment2025 Valuation Update & Consistent Growth Stock Picks - baoquankhu1.vn
Is Evoke Pharma Inc.’s ROE strong enoughWeekly Trade Summary & Weekly Chart Analysis and Guides - bollywoodhelpline.com
IPO Launch: Is Evoke Pharma Inc stock heavily shortedJuly 2025 Fed Impact & Low Risk Entry Point Guides - baoquankhu1.vn
Evoke Pharma Leads Stock Performance with 149.43% Return Over Past Year - Markets Mojo
Evoke Pharma Achieves 313.53% Return, Leading Recent Stock Performers - Markets Mojo
Is Evoke Pharma Inc. a speculative investmentEarnings Risk Report & Fast Gaining Stock Strategy Reports - bollywoodhelpline.com
Evoke Pharma (NASDAQ:EVOK) Stock Price Passes Above 50 Day Moving Average – Time to Sell? - Defense World
US Market Wrap: What are analysts price targets for Evoke Pharma Inc2025 Fundamental Recap & Low Risk Entry Point Guides - baoquankhu1.vn
AI Stocks: Is Evoke Pharma Inc a speculative investmentJuly 2025 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Wall Street Recap: Will Evoke Pharma Inc benefit from seasonalityJuly 2025 PostEarnings & Low Risk Entry Point Guides - baoquankhu1.vn
Evoke Pharma Leads Micro-Cap Stocks with 137.07% Return Over Past Year - Markets Mojo
Evoke Pharma Leads Micro-Cap Stocks with 149.43% Return Over Past Year - MarketsMojo
Evoke Pharma Achieves 304.41% Return, Leading Micro-Cap Stock Performance - MarketsMojo
Will Evoke Pharma Inc. stock benefit from commodity prices2025 AllTime Highs & Low Risk High Win Rate Picks - Улправда
How The Story Behind Evoke (LSE:EVOK) Is Changing With Takeover Terms And UK Gaming Tax - Yahoo Finance
Evoke Pharma Achieves 313.53% Return Amid Mixed Micro-Cap Performance - Markets Mojo
What technical charts say about Evoke Pharma Inc. stock - ulpravda.ru
Will Evoke Pharma Inc. stock keep outperforming rivalsJuly 2025 Fed Impact & Daily Risk Controlled Trade Plans - Улправда
Will Evoke Pharma Inc. stock gain from strong economyWeekly Profit Analysis & High Accuracy Trade Alerts - ulpravda.ru
Why Evoke Pharma Inc. stock is considered a top pickEarnings Trend Report & Fast Entry High Yield Stock Tips - Улправда
How Evoke Pharma Inc. stock performs in rate cut cyclesWeekly Trade Summary & Capital Efficiency Focused Strategies - Улправда
How Evoke Pharma Inc. stock performs in stagflationTrade Analysis Report & Stepwise Swing Trade Plans - ulpravda.ru
Evoke Pharma, Inc.Common Stock (NQ: EVOK - FinancialContent
How Evoke Pharma Inc. stock performs after earningsSwing Trading Watchlist & Free Strong Return On Assets - ulpravda.ru
Evoke Pharma Leads Pharmaceuticals Sector with 137.07% Annual Return - Markets Mojo
Operating cash flow per share of Evoke Pharma, Inc. – SWB:EV0 - TradingView — Track All Markets
Evoke Pharma Achieves 304.41% Return Amid Strong Market Performance - Markets Mojo
Evoke Pharma Achieves 313.53% Return; InnovAge Holding Up 31.39% - Markets Mojo
Evoke Pharma Achieves 313.53% Return Amid Market Volatility - Markets Mojo
Evoke Pharma Leads with 124.95% Return Among Notable Stock Performers - Markets Mojo
Evoke Pharma Leads Stock Performance with 148.87% Return in Pharmaceuticals Sector - Markets Mojo
Evoke Pharma Leads with 148.87% Return Among High-Performing Stocks - Markets Mojo
Bank Watch: Will Evoke Pharma Inc stock gain from strong economyQuarterly Earnings Report & Smart Allocation Stock Reports - moha.gov.vn
Evoke Pharma Leads Impressive Stock Returns with 126.34% Gain - Markets Mojo
Evoke Pharma Achieves 318.7% Return, Leading Pharmaceutical Stocks Performance - Markets Mojo
Evoke Pharma Leads Six-Month Stock Returns with 316.67% Gain - Markets Mojo
Evoke Pharma Achieves 316.67% Return, Leading Pharmaceutical Sector Performance - Markets Mojo
Evoke Pharma, Inc. Financial Disclosures & Filings - TradingView — Track All Markets
Evoke Pharma Leads Stocks with 124.49% Return in Pharmaceuticals Sector - Markets Mojo
Evoke Pharma Leads Six-Month Stock Returns with 298.55% Gain - Markets Mojo
Evoke Pharma Achieves 340% Return, Leading Recent Stock Performers - Markets Mojo
Evoke Pharma Leads Stock Returns with 121.77% Gain Over Past Year - Markets Mojo
Evoke Pharma Leads Stock Performance with 100.36% Return in Past Year - Markets Mojo
Evoke Pharma Inc Stock (EVOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):